

JUN 24 2011

## 510(k) SUMMARY

### Biopsy Handy / MRI Biopsy Handy

**Submitter:** Somatex Medical Technologies GmbH  
Rheinstrasse 7d  
14513 Teltow  
Germany  
Phone: +49 3328 3076 13  
Fax: +49 3328 3076 99

**Official Correspondent:** Susanne Raab  
Regulatory Affairs Consultant  
1480 Cambridge Street  
Cambridge, MA 02139  
Phone: 617 547 0628  
Fax: 617 520 2136  
e-mail: sbraab@comcast.net

**Trade Name:** Biopsy Handy / MRI Biopsy Handy

**Common Name:** Semiautomatic Biopsy System

**Classification Name:** Biopsy Instrument, 21 C.F.R. 876.1075

**Regulatory Class:** II

**Product Code:** KNW

**Device Description:** The Biopsy Handy and the MRI Biopsy Handy are sterile, single use, semiautomatic percutaneous soft tissue biopsy systems each consisting of the following major components: a device handle, a cannula, a stylet button, a stylet with a specimen chamber, a hub of the cannula, a guide bush, a slide and a pressure spring. In addition, the cannulas of the

proposed devices will be delivered with a protective tube.

**Intended Use:**

The Biopsy Handy and MRI Biopsy Handy are intended to obtain diagnostic samples of soft tissues for histological examination during a percutaneous biopsy procedure. Both devices are indicated to be used with ultrasound or CT-Guidance techniques. Only the MRI Biopsy Handy is indicated to be used with magnetic resonance imaging (MRI) techniques.

**Substantial  
Equivalence:**

The Biopsy Handy and MRI Biopsy Handy are substantially equivalent to the Speedybell manufactured by Biopsybell S.A.S., which has been cleared by FDA on August 17, 2001 (K010735), and the Daum Biopsygun manufactured by Daum Corp., which has been cleared by FDA on March 6, 1998 (K974576). Specifically, the proposed devices and the predicate devices are all intended to obtain diagnostic samples of soft tissues for histological examination during a percutaneous biopsy procedure. In addition, the proposed devices and the predicate device Speedybell are indicated to be used with ultrasound or CT-Guidance techniques. Finally, both the MRI Biopsy Handy and the predicate device Daum Biopsygun are indicated to be used with magnetic resonance imaging (MRI) techniques.

Furthermore, the Biopsy Handy and MRI Biopsy Handy are identical or similar in technology, design and material to the

predicate devices. Both the proposed and the predicate devices consist of the same primary components and the component materials of the proposed device and the predicate devices are substantially equivalent.

Based on the same intended use and the similarities in technology, design and materials, the Biopsy Handy and MRI Biopsy Handy are substantially equivalent to their predicate devices. The minor technological differences between the proposed devices and the predicate devices do not raise new questions of safety and effectiveness.

Finally, biocompatibility, sterility, packaging and MR-testing demonstrate the safety and effectiveness of the proposed devices.

**Date Prepared:** February 24, 2011



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room -WO66-G609  
Silver Spring, MD 20993-0002

Somatex Medical Technologies GmbH  
% Ms. Susanne Raab  
Regulatory Affairs Consultant  
1480 Cambridge Street  
Cambridge, Massachusetts 02139

JUN 24 2011

Re: K102771

Trade/Device Name: Biopsy Handy/MRD Biopsy Handy  
Regulation Number: 21 CFR 876.1075  
Regulation Name: Gastroenterology-urology biopsy instrument  
Regulatory Class: Class II  
Product Code: KNW  
Dated: June 23, 2011  
Received: June 24, 2011

Dear Ms. Raab:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", with a long horizontal flourish extending to the right.

Mark N. Melkerson  
Director  
Division of Surgical, Orthopedic  
And Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indication for Use

510(k) Number (if known): K102771

Device Name: Biopsy Handy / MRI Biopsy Handy

Indications for Use:

The **Biopsy Handy** and **MRI Biopsy Handy** are intended to obtain diagnostic samples of soft tissues for histological examination during a percutaneous biopsy procedure. Both devices are indicated to be used with ultrasound or CT-Guidance techniques. Only the **MRI Biopsy Handy** is indicated to be used with magnetic resonance imaging (MRI) techniques.

Prescription Use   X    
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
Division of Surgical, Orthopedic,  
and Restorative Devices

510(k) Number K102771 Page 1 of 1